TRUE Private Wealth Advisors raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% during the second quarter, Holdings Channel reports. The institutional investor owned 15,290 shares of the company’s stock after buying an additional 843 shares during the period. TRUE Private Wealth Advisors’ holdings in Johnson & Johnson were worth $1,854,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of JNJ. Daiwa SB Investments Ltd. purchased a new stake in Johnson & Johnson during the first quarter valued at about $296,000. Integrated Investment Consultants LLC increased its stake in Johnson & Johnson by 2.9% in the first quarter. Integrated Investment Consultants LLC now owns 10,595 shares of the company’s stock valued at $1,153,000 after buying an additional 300 shares in the last quarter. Wunderlich Securities Inc. increased its stake in Johnson & Johnson by 4.7% in the first quarter. Wunderlich Securities Inc. now owns 4,083 shares of the company’s stock valued at $441,000 after buying an additional 185 shares in the last quarter. Franklin Street Advisors Inc. NC increased its stake in Johnson & Johnson by 17.6% in the first quarter. Franklin Street Advisors Inc. NC now owns 57,791 shares of the company’s stock valued at $6,253,000 after buying an additional 8,653 shares in the last quarter. Finally, Prospera Financial Services Inc increased its stake in Johnson & Johnson by 3.4% in the first quarter. Prospera Financial Services Inc now owns 13,906 shares of the company’s stock valued at $1,503,000 after buying an additional 451 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.3366% during trading on Tuesday, hitting $118.4101. The stock had a trading volume of 3,460,898 shares. Johnson & Johnson has a one year low of $92.58 and a one year high of $126.07. The firm’s 50-day moving average is $119.10 and its 200-day moving average is $116.88. The firm has a market cap of $323.96 billion, a P/E ratio of 22.0667 and a beta of 0.62.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. The business earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. Equities research analysts forecast that Johnson & Johnson will post $6.69 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is 60.15%.
Several research firms recently commented on JNJ. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, June 6th. BMO Capital Markets reissued an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Jefferies Group boosted their target price on Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a research note on Thursday, August 4th. Finally, Deutsche Bank AG reissued a “hold” rating and set a $142.00 target price (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $120.19.
In related news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.